KR20190022682A - Ards에 대한 리포뉴클레오티드-기반 요법 - Google Patents

Ards에 대한 리포뉴클레오티드-기반 요법 Download PDF

Info

Publication number
KR20190022682A
KR20190022682A KR1020197002042A KR20197002042A KR20190022682A KR 20190022682 A KR20190022682 A KR 20190022682A KR 1020197002042 A KR1020197002042 A KR 1020197002042A KR 20197002042 A KR20197002042 A KR 20197002042A KR 20190022682 A KR20190022682 A KR 20190022682A
Authority
KR
South Korea
Prior art keywords
cdp
composition
choline
ards
dag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197002042A
Other languages
English (en)
Korean (ko)
Inventor
이안 크리스토퍼 데이비스
Original Assignee
오하이오 스테이트 이노베이션 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오하이오 스테이트 이노베이션 파운데이션 filed Critical 오하이오 스테이트 이노베이션 파운데이션
Publication of KR20190022682A publication Critical patent/KR20190022682A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197002042A 2016-06-27 2017-06-27 Ards에 대한 리포뉴클레오티드-기반 요법 Ceased KR20190022682A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355096P 2016-06-27 2016-06-27
US62/355,096 2016-06-27
PCT/US2017/039545 WO2018005527A1 (en) 2016-06-27 2017-06-27 Liponucleotide-based therapy for ards

Publications (1)

Publication Number Publication Date
KR20190022682A true KR20190022682A (ko) 2019-03-06

Family

ID=60786443

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002042A Ceased KR20190022682A (ko) 2016-06-27 2017-06-27 Ards에 대한 리포뉴클레오티드-기반 요법

Country Status (9)

Country Link
US (2) US10874684B2 (enExample)
EP (2) EP3474853A4 (enExample)
JP (1) JP2019518798A (enExample)
KR (1) KR20190022682A (enExample)
CN (1) CN109475554A (enExample)
AU (1) AU2017289278A1 (enExample)
CA (1) CA3029005A1 (enExample)
SG (1) SG11201811595SA (enExample)
WO (1) WO2018005527A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518798A (ja) * 2016-06-27 2019-07-04 オハイオ・ステイト・イノベーション・ファウンデーション リポヌクレオチドに基づくａｒｄｓの治療
EP3645009A4 (en) * 2017-06-27 2021-03-31 The Ohio State Innovation Foundation LIPONUCLEOTIDE THERAPY FOR COPD
US20230181509A1 (en) * 2020-03-31 2023-06-15 Diffusion Pharmaceuticals Llc The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease
CA3177338A1 (en) * 2020-05-01 2021-11-04 Marco A. Chacon Method for treating respiratory viral infections comprising administration of fatty acid compositions
US20250177541A1 (en) * 2022-03-11 2025-06-05 Arizona Board Of Regents On Behalf Of Arizona State University Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection
WO2023177995A2 (en) * 2022-03-18 2023-09-21 Ohio State Innovation Foundation Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
CA1321994C (en) * 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
KR100290132B1 (ko) * 1994-07-01 2001-05-15 마이클 바마트 전신 염증 및 염증성 간염 치료용 피리미딘 누클레오티드 전구체
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
EP2332546A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
DK1453844T3 (da) * 2001-11-21 2014-02-10 Univ Aarhus Anvendelse af glycosider af mono- og diacylglycerol som anti-inflammatoriske midler
EA012138B1 (ru) * 2004-11-17 2009-08-28 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим Применение конъюгатов липидов при лечении заболеваний
PT1888081T (pt) * 2005-05-23 2017-03-01 Massachusetts Inst Technology Composições contendo pufa e seus métodos de utilização
CN101506218A (zh) * 2005-05-23 2009-08-12 麻省理工学院 含有多不饱和脂肪酸的组合物及其使用方法
JP2019518798A (ja) * 2016-06-27 2019-07-04 オハイオ・ステイト・イノベーション・ファウンデーション リポヌクレオチドに基づくａｒｄｓの治療
EP3645009A4 (en) * 2017-06-27 2021-03-31 The Ohio State Innovation Foundation LIPONUCLEOTIDE THERAPY FOR COPD
WO2019005901A1 (en) * 2017-06-27 2019-01-03 Ohio State Innovation Foundation Liponucleotide-based therapy for asthma

Also Published As

Publication number Publication date
EP3474853A1 (en) 2019-05-01
WO2018005527A1 (en) 2018-01-04
SG11201811595SA (en) 2019-01-30
EP4292651A3 (en) 2024-03-13
AU2017289278A1 (en) 2019-01-17
EP4292651A2 (en) 2023-12-20
US10874684B2 (en) 2020-12-29
EP3474853A4 (en) 2020-02-19
US20190134074A1 (en) 2019-05-09
JP2019518798A (ja) 2019-07-04
CA3029005A1 (en) 2018-01-04
CN109475554A (zh) 2019-03-15
US20210069225A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
KR20190022682A (ko) Ards에 대한 리포뉴클레오티드-기반 요법
US20240245646A1 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
KR20160093000A (ko) 창자 과투과성을 치료하기 위한 티로신 하이드록실라제 억제제
WO2014013664A1 (ja) インフルエンザウイルス感染症の予防・治療剤
JP2016516773A5 (enExample)
WO2012156565A1 (es) Preparación inyectable de melatonina
WO2011097148A3 (en) Use of oral heparin preparations to treat urinary tract diseases and conditions
US11154621B2 (en) Liponucleotide-based therapy for COPD
EP4104825A1 (en) Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea
HK40003888A (en) Liponucleotide-based therapy for ards
WO2022213870A1 (zh) 通过口服给药抑制CD4+Treg细胞的药物和方法
US20250170246A1 (en) Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection
TWI889805B (zh) 器官損傷的預防和治療
JPWO2020037152A5 (enExample)
CN110891574A (zh) 用于预防和/或治疗肝细胞癌的美格列明
HK40041872A (en) Method for preventing and/or treating aging-associated cognitive impairment
TW201100072A (en) A pharmaceutical composition for treating septic shock
HK1261918B (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200604

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220428

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220120

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I